333123-61-61-63-6121234321-63-63-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of a bacterial infection mediated by F. tularensis.
33311-623-61-61-63-612123432P41-63-63-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of a bacterial infection mediated by spirochetes.
111-622 is the compound for use as a medicament and a pharmaceutical composition comprising the compound as well as a method of treatment or prevention a disease mediated by microbes making use thereof.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
00 is C1 or I, preferably C1; a process for preparing said compound as well as use of said compound and a process for preparing 12-epi-mutilin derivatives.
33311-623-61-61-63-612123432p41-63-63-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of a disease mediated by a virus.
33123-61-61-63-61212343241-63-63-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of an inflammatory disease which is not mediated by bacteria.
A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
A61K 31/24 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteroraryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a pharmaceutically acceptable salt and/or solvate, prodrug or metabolite, wherein the naturally occurring pleuromutilin is of formula (I) for the specific use in the treatment or prevention of a disease mediated by a virus. The invention further relates to 12-epi-12-desvinyl-14-O-[(Piperidin-4-ylsulfanyl]-acetyl]-12- [2-(3-methyl-pyrazin-2-yl)-ethenyl]-mutilin and its therapeutic uses.
A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
The present invention relates to purification methods of pleuromutilin (I) by means of crystallisation and/or recrystallisation. The process according to the present invention is carried out in the presence of i-propylacetate.
C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation
C07C 69/675 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides saturés d'acides hydroxycarboxyliques saturés
10.
INJECTABLE PHARMACEUTICAL FORMULATIONS OF LEFAMULIN
The present invention relates to an injectable pharmaceutical formulation comprising a compound of formula (I), said formulation being buffered to a pharmaceutically acceptable pH-value, especially a pH-value of from 2 to 6, in particular a pH value of from 3 to 5.5, preferred a pH-value of about 4 to 5, particularly preferred about 5. Compound (I) is lefamulin (BC-3781) which has antibiotic properties.
brevets